Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.
about
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Failure-free survival after initial systemic treatment of chronic graft-versus-host diseaseAutologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host diseaseA randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.How we treat chronic graft-versus-host disease.Treatment of chronic graft-versus-host disease: Past, present and future.Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioningAllogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsRelapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array TestingPosttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationAllogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.Clinical trials in chronic myeloid leukemia.Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.The role of novel immunotherapies in non-Hodgkin lymphoma.Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low-weight child.Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete re
P2860
Q33416874-DA37FEF1-609F-4A46-B5FE-C31EB1AB47FFQ34077787-DA3509B7-860D-4040-9ED7-8AC6869979AAQ34170406-D1603C71-B621-4EB2-AAAD-D615B3A32D63Q34272547-0D4FEC1D-90BB-4EAB-AFDA-C6CCBCCE1578Q34272554-02AC6A81-DC7C-428D-9ED5-AE62FFF14356Q35004923-897C2413-145C-477D-AFA8-E781B745DC49Q35524687-895A352B-4E30-46CD-A2CD-574D2E649E15Q35752737-FAC69772-8F1B-4FA0-B2A6-FBAFF04D5A2FQ36319726-39DA0332-0E61-4393-9F79-9E4311AF138EQ36461915-3CE73FBE-0E45-4B66-A63C-3C2CE2382176Q36635154-41278E2C-BA0A-4D44-B295-DCC713EA5B93Q36700499-951FEB27-F70B-4F4D-A455-AA2C42DA2B0FQ36709850-9A50C20C-E00C-42F9-97CA-97F124EE305AQ36763834-1A82A181-C85B-4AC3-9FDB-256B2A1C7788Q36774150-D1C17C42-2FC6-4FDE-B998-94C05D3BCCFDQ36945976-C0E0464D-AE46-4ED2-91D8-F0D512C7937BQ36980277-EBC857AB-7478-470A-AC8C-56597021271DQ37559148-06BBBC3E-D378-4BF4-AA70-62AD7B5035EEQ37955235-29B42D6B-D725-416E-8AFF-77B0E482F13CQ37994134-DAA8AE34-ACF4-434F-BB2E-5A6FDA9FE305Q40106226-3C40D262-41AB-4F5E-8BF6-7120A674E143Q41695080-B9E7AC4F-84EB-40E9-88D7-C3117E3C88CBQ44243900-5229422E-44A8-4FAB-8B03-46588FA978A3Q45874732-5C229463-193D-425A-ABC8-DD73B94BDDDCQ46721176-D6446771-6F3F-46EF-B11E-ABDE1A5CE7E0Q47255174-D9D6B8B6-2732-45AD-B0C2-B0F003DA78E1Q47865655-A982D65B-94FA-4E43-8B04-B4869ED66FD1Q50043532-F8760C9D-CF69-4D5B-B4D8-4F80FCE680A2Q54275690-94E8004E-06E5-47EE-8FC1-BF442A390D75
P2860
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Influence of immunosuppressive ...... opoietic cell transplantation.
@ast
Influence of immunosuppressive ...... opoietic cell transplantation.
@en
type
label
Influence of immunosuppressive ...... opoietic cell transplantation.
@ast
Influence of immunosuppressive ...... opoietic cell transplantation.
@en
prefLabel
Influence of immunosuppressive ...... opoietic cell transplantation.
@ast
Influence of immunosuppressive ...... opoietic cell transplantation.
@en
P2093
P2860
P50
P1433
P1476
Influence of immunosuppressive ...... opoietic cell transplantation.
@en
P2093
Edus H Warren
Mary E D Flowers
Paul A Carpenter
Paul J Martin
Stephanie J Lee
Yoshihiro Inamoto
P2860
P304
P356
10.1182/BLOOD-2011-01-330217
P407
P577
2011-06-01T00:00:00Z